Literature DB >> 6253448

Phosphomannosyl-enzyme receptors in rat liver. Subcellular distribution and role in intracellular transport of lysosomal enzymes.

H D Fischer, A Gonzalez-Noriega, W S Sly, D J Morré.   

Abstract

beta-Hexosaminidase B purified from human fibroblast secretions was used as a ligand to study phosphomannosyl-enzyme receptors in membranes from rat tissues. Enzyme binding to rat liver membranes was saturable, competitively inhibited by mannose 6-phosphate, not dependent on calcium, and destroyed by prior treatment of the hexosaminidase with either alkaline phosphatase or endoglycosidase H. Most (90%) of the phosphomannosyl-enzyme receptors were found in endoplasmic reticulum, Golgi apparatus, and lysosomes; 9.5% in the plasma membrane, and less than 1% in nuclei and mitochondria. Receptors were vesicle-enclosed in all fractions except plasma membrane. Receptors in the endoplasmic reticulum apparently were occupied by endogenous ligands, but most receptors in lysosomes and plasma membrane were unoccupied. Most of the endogenous beta-hexosaminidase was in lysosomes and was released from vesicles by detergent treatment. Displacement of the residual receptor-bound endogenous beta-hexosaminidase (mostly in endoplasmic reticulum and Golgi apparatus) from detergent-treated membranes by mannose 6-phosphate released high uptake enzyme with properties expected for phosphomannosyl-enzymes. Mannose 6-phosphate-inhibitable enzyme receptor activity was found in nine rat organs and correlated roughly with their lysosomal enzyme content. These data support a general model for lysosomal enzyme transport in which the phosphomannosyl-enzyme receptor acts as a vehicle for delivery of newly synthesized acid hydrolases from the endoplasmic reticulum to lysosomes.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6253448

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

Review 1.  Enzyme-replacement therapy: problems and prospects.

Authors:  B Rademaker; J Raber
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

2.  Characteristics of lysosomal phosphomannosyl-enzyme receptors in the rat heart.

Authors:  V S Marjomäki; A Salminen
Journal:  Basic Res Cardiol       Date:  1987 May-Jun       Impact factor: 17.165

3.  Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis.

Authors:  A M Cataldo; J L Barnett; C Pieroni; R A Nixon
Journal:  J Neurosci       Date:  1997-08-15       Impact factor: 6.167

Review 4.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

5.  Properties of the Syrian hamster phosphomannosyl receptor: an aggregate of low molecular weight proteins.

Authors:  T Maler; B B Rosenblum; G W Jourdian
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

6.  Synthesis of beta-hexosaminidase in cell-free translation and in intact fibroblasts: an insoluble precursor alpha chain in a rare form of Tay-Sachs disease.

Authors:  R L Proia; E F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

7.  Specific binding of leukotriene C4 to ileal segments and subcellular fractions of ileal smooth muscle cells.

Authors:  S Krilis; R A Lewis; E J Corey; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

8.  Cellular and lysosomal uptake of methylamine in isolated rat hepatocytes.

Authors:  A E Solheim; P O Seglen
Journal:  Biochem J       Date:  1983-03-15       Impact factor: 3.857

9.  The effect of chloroquine on the distribution of newly synthesized and old beta-hexosaminidase in fibroblasts.

Authors:  G D Vladutiu
Journal:  Biochem J       Date:  1982-12-15       Impact factor: 3.857

10.  alpha-L-iduronidase therapy for mucopolysaccharidosis type I.

Authors:  Jakub Tolar; Paul J Orchard
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.